SpringerProtocols: Abstract: Transactivation and Transrepression Studies with p53

Transactivation and Transrepression Studies with p53

By: Mariano J. Scian², Rebecca Frum³, Swati Palit Deb^{2 4}, Sumitra Deb^{2 4}

Abstract

Full Text

Download PDF (151K)

The methods outlined in this chapter are designed to facilitate the study of the transactivation and transrepression properties of p53 (as well as p63 and p73). Once a gene of interest is identified, its presumptive promoter region can be cloned upstream of a luciferase gene in a plasmid. The most common reason for transfection experiments is to study gene expression patterns in the presence or absence of a particular gene product (e.g., p53). Three methods of transfection are outlined in this chapter: (i) cationic lipofection; (ii) calcium phosphate precipitation; and (iii) BES precipitation. The first method is ideal for the study of transactivation and transrepression properties of p53 (or other transcription factors). The last two are more suited for experiments where larger numbers of transfected cells are needed. Several examples of transfections and their respective results are provided.

Affiliation(s): (2) Department of Biochemistry, Virginia Commonwealth University, Richmond, VA
(3) Department of Biochemistry, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
(4) The Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

Book Title: p53 Protocols

Series: Methods in Molecular Biology | Volume: 234 | Pub. Date: Jun-20-2003 | Page Range: 93-110 | DOI: 10.1385/1-59259-408-5:93

Subject: Cancer Research

Key Words: p53 - promoter studies - transactivation - transrepression - transfection methods

References

Download References

1.	Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323–331.

2.	Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307–310.

3.	Prives, C. and Hall, P. A. (1999) The p53 pathway. J. Pathol. 187, 112–126.

4.	Lane, D. P. (1994) p53 and human cancers. Br. Med. Bull. 50, 582–599.

5.	Donehower, L. A. and Bradley, A. (1993) The tumor suppressor p53. Biochim. Biophys. Acta 1155, 181–205.

6.	Kern, S. E., Kinzler, K. W., Bruskin, A., et al. (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708–1711.

7.	Sun, Y. (2000) Identification and characterization of genes responsive to apoptosis: application of DNA chip technology and mRNA differential display. Histol. Histopathol. 15, 1271–1284.

8.	Okamura, S., Ng, C. C., Koyama, K., Takei, Y., Arakawa, H., Monden, M., and Nakamura, Y. (1999) Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol. Res. 11, 281–285.

9.	Murphy, M., Hinman, A., and Levine, A. J. (1996) Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10, 2971–2980.

10.	Farmer, G., Friedlander, P., Colgan, J., Manley, J. L., and Prives, C. (1996) Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24, 4281–4288.

11.	Rishi, A. K., Hsu, C. K., Li, X. S., Hussain, A., Gerald, T. M., and Fontana, J. A. (1997) Transcriptional repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 gene mediated by cis elements present in the 3′-untranslated region. Cancer Res. 57, 5129–5136.

12.	Yu, C. L., Driggers, P., Barrera-Hernandez, G., Nunez, S. B., Segars, J. H., and Cheng, S. (1997) The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem. Biophys. Res. Commun. 239, 617–620.

13.	Kubicka, S., Kuhnel, F., Zender, L., et al. (1999) p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J. Biol. Chem. 274, 32,137–32,144.

14.	Krause, K., Wasner, M., Reinhard, W., et al. (2000) The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 28, 4410–4418.

15.	Johnson, R. A., Ince, T. A., and Scotto, K. W. (2001) Transcriptional repression by p53 through direct binding to a novel DNA element. J. Biol. Chem. 276, 27,716–27,720.

16.	De Laurenzi, V. and Melino, G. (2000) Evolution of functions within the p53/p63/p73 family. Ann. NY Acad. Sci. 926, 90–100.

17.	Ichimiya, S., Nakagawara, A., Sakuma, Y., et al. (2000) p73: structure and function. Pathol. Int. 50, 589–593.

18.	Arrowsmith, C. H. (1999) Structure and function in the p53 family. Cell Death Differ. 6, 1169–1173.

19.	Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Wang, J. Y., and Melino, G. (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 113, 1661–1670.

20.	Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Melino, G., and Wang, J.Y. (1999) Structure, function and regulation of p63 and p73. Cell Death Differ. 6, 1146–1153.

21.	Deb, D., Lanyi, A., Scian, M., et al. (2001) Differential modulation of cellular and viral promoters by p73 and p53. Int. J. Oncol. 18, 401–409.

22.	Takagi, S., Ueda, Y., Hijikata, M., and Shimotohno, K. (2001) Overproduced p73alpha activates a minimal promoter through a mechanism independent of its transcriptional activity. FEBS Lett. 509, 47–52.

23.	Diller, L., Kassel, J., Nelson, C. E., et al. (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol. 10, 5772–5781.

24.	Subler, M. A., Martin, D. W., and Deb, S. (1992) Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66, 4757–4762.

25.	Gentile, M., Bergman Jungestrom, M., Olsen, K. E., Soderkvist, P., and Wingren, S. (1999) p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur. J. Cancer 35, 1202–1207.

26.	Brown, D. R., Thomas, C. A., and Deb, S. P. (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J. 17, 2513–2525.

Comments (Loading...)

Post comment/View all comments